These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 20827162)

  • 1. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
    Yukl SA; Shergill AK; McQuaid K; Gianella S; Lampiris H; Hare CB; Pandori M; Sinclair E; Günthard HF; Fischer M; Wong JK; Havlir DV
    AIDS; 2010 Oct; 24(16):2451-60. PubMed ID: 20827162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
    Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
    AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
    McMahon D; Jones J; Wiegand A; Gange SJ; Kearney M; Palmer S; McNulty S; Metcalf JA; Acosta E; Rehm C; Coffin JM; Mellors JW; Maldarelli F
    Clin Infect Dis; 2010 Mar; 50(6):912-9. PubMed ID: 20156060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.
    Negredo E; Massanella M; Puertas MC; Buzón MJ; Puig J; Pérez-Alvárez N; Pérez-Santiago J; Bonjoch A; Moltó J; Jou A; Echeverría P; Llibre JM; Martínez-Picado J; Clotet B; Blanco J
    J Antimicrob Chemother; 2013 Oct; 68(10):2358-62. PubMed ID: 23677919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
    Gandhi RT; Zheng L; Bosch RJ; Chan ES; Margolis DM; Read S; Kallungal B; Palmer S; Medvik K; Lederman MM; Alatrakchi N; Jacobson JM; Wiegand A; Kearney M; Coffin JM; Mellors JW; Eron JJ;
    PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20711481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
    Puertas MC; Gómez-Mora E; Santos JR; Moltó J; Urrea V; Morón-López S; Hernández-Rodríguez A; Marfil S; Martínez-Bonet M; Matas L; Muñoz-Fernández MA; Clotet B; Blanco J; Martinez-Picado J
    J Antimicrob Chemother; 2018 Jul; 73(7):1940-1948. PubMed ID: 29635527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
    Massanella M; Esteve A; Buzón MJ; Llibre JM; Puertas MC; Gatell JM; Domingo P; Stevenson M; Clotet B; Martinez-Picado J; Blanco J;
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):152-60. PubMed ID: 23392458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
    Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
    J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
    Yukl SA; Gianella S; Sinclair E; Epling L; Li Q; Duan L; Choi AL; Girling V; Ho T; Li P; Fujimoto K; Lampiris H; Hare CB; Pandori M; Haase AT; Günthard HF; Fischer M; Shergill AK; McQuaid K; Havlir DV; Wong JK
    J Infect Dis; 2010 Nov; 202(10):1553-61. PubMed ID: 20939732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
    Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
    AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
    Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
    J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
    Hatano H; Hayes TL; Dahl V; Sinclair E; Lee TH; Hoh R; Lampiris H; Hunt PW; Palmer S; McCune JM; Martin JN; Busch MP; Shacklett BL; Deeks SG
    J Infect Dis; 2011 Apr; 203(7):960-8. PubMed ID: 21402547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
    Taiwo B; Zheng L; Gallien S; Matining RM; Kuritzkes DR; Wilson CC; Berzins BI; Acosta EP; Bastow B; Kim PS; Eron JJ;
    AIDS; 2011 Nov; 25(17):2113-22. PubMed ID: 21857490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
    Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
    AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
    Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.